The pathologies targeted by Cytokines Biotech's nG-INF include viral, bacterial, fungal and parasitic infections as well as various auto-immune conditions and cancer, and emphasis will be initially put on opportunistic infections in HIV patients, antibiotic-resistant bacteria and some rare types of cancers.īy engaged in the development and marketing of novel immun therapeutic applications, A5 Labs can become a fully integrated global biopharmaceutical company by conducting internal late stage development, registration and commercialization of naturrrally produced interferon products using A5 Labs 's novel production technology. Such applications include the diagnostic, the prevention and the treatment of various animal and human diseases. AFLB's management also feel honored for this review of A5 Labs as it will provide a transparent picture for investors.Ī5 Labs are a specialty biotechnology company engaged in the development and marketing of novel immun therapeutic applications of a natural Gamma ? Interferon (nG-IFN). The coverage of A5 Labs from Emerging Stock Report shows the AFLB scrip has potential for growth in the future. ESR management consists of top professionals in the industry which help investors make crucial investment decisions. ESR usually initiates research in emerging growth companies and its deep level research coverage includes real time news, sector specific research, market commentary, financial and data reviews. Emerging Stock Report is one of the leaders in conducting independent investment research in the United States. Emerging Stock Report is a leading investment Research Company which has recently started independent research coverage on A5 Laboratories Inc.
0 kommentar(er)
